Different screening frequencies of carbapenem-resistant Enterobacteriaceae in patients undergoing hematopoietic stem cell transplantation: which one is better?

Ting-Ting Yang, Xue-Ping Luo, Qing Yang, Hong-Chao Chen, Yi Luo, Yan-Min Zhao, Yi-Shan Ye, Xiao-Yu Lai, Jian Yu, Ya-Min Tan, Guo-Qing Wei, He Huang, and Ji-Min Shi

Abstract

Background: A consensus has been reached that carbapenem-resistant Enterobacteriaceae (CRE) screening in immunosuppressed individuals can reduce the incidence of CRE bloodstream infection (BSI).

Methods: We retrospectively studied the clinical data of 395 consecutive HSCT patients from September 2017 to April 2019. From September 2017 to June 2018 (period 1), 200 patients received single CRE screening before transplantation. From July 2018 to April 2019 (period 2), 195 patients received continuous weekly CRE screening after admission. For patients colonized with CRE, targeted managements were received: (1) contact precautions and (2) preemptive CRE-targeted treatment if necessary.

Results: During period 1, 3 patients with CRE colonization were detected (1.5%). The CRE BSI rate was 2.0% (4 patients), and the related 30-day mortality was 50.0% (2 out of 4 patients). During period 2, 21 patients with CRE colonization were detected, and the detection rate was significantly higher than that in period 1 (P < 0.001). Of the 21 colonized patients, 4 (19.0%) patients were identified as positive for CRE at the first screening, 5 (23.8%) were identified at the second screening, and the remaining 12 (57.1%) were identified at the third or later screening. The CRE BSI rate decreased to 0.5% (1/195), and there were no CRE-related death.

Fifteen colonized patients developed neutropenic fever. Thirteen colonizers were preemptively treated with tigecycline within 24 h of fever onset, and they achieved rapid temperature control. One colonizer received tigecycline later than 48 h after fever onset and ultimately survived due to the addition of polymyxin. The other received tigecycline later than 72 h after fever onset and died of septic shock.

Conclusion: The increase in screening frequency contributed to the detection of patients with CRE colonization. Targeted managements for these colonized patients may contribute to reducing the incidence and mortality of CRE BSI, therefore improving the prognosis of patients.

Keywords: Carbapenem-resistant Enterobacteriaceae, Hematopoietic stem cell transplantation, Continuous screening, Bloodstream infection

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

With the extensive use of carbapenems, a global dissemination of carbapenem-resistant Enterobacteriaceae (CRE) has been reported in recent decades [1]. A recent national multicenter study from 25 provinces in China reported that the rate of carbapenem resistance in Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) was up to 0.6–3.6% and 1.2–18.9%, with 1.8 and 12.3% in Zhejiang Province, respectively, which has increased year after year [2]. Long-term hospitalization, frequent use of broad-spectrum antibiotics, high-dose chemotherapy, neutropenia, compromised immunity, and gastrointestinal mucosal destruction are risk factors favoring CRE colonization and bloodstream infections (BSIs) in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT) [3–8]. The overall incidence of BSIs caused by CRE in HSCT recipients is approximately 1.8–2%. Due to the lack of effective antibiotic treatment, the death rate of CRE BSIs after HSCT is high (51–65%) [3, 6, 9, 10]. Increasing studies have revealed the importance of preemptive intervention in the prevention and treatment of CRE BSIs.

Gut colonization by CRE is an independent risk factor for CRE infection [7, 8, 11, 12]. An Italian multicenter study showed that in patients who underwent autologous and allogeneic HSCT, the CRE colonization rates were 1 and 2.4%, respectively. Of these patients with CRE colonization, 25.8 and 39.2% subsequently developed CRE BSIs, which was significantly more frequent than the rate of general hospitalized patients (16.5%) [6]. Early identification of CRE colonization made it easier to adopt early strategies to control CRE dissemination [13]. Many guidelines and studies also recommend HSCT patients as a target population for CRE screening, and consider stool as the preferred sample for screening because of good patient compliance and few side effects [5, 14–18]. However, for HSCT centers where CRE are endemic nosocomial pathogens, the effect of weekly active screening on morbidity and mortality of CRE BSIs has rarely been reported.

In our center, the first case of CRE BSI was identified in May 2016, and the incidence and related mortality of CRE BSIs from May 2016 to August 2017 was 1.9 and 66.7%, respectively. Given the high CRE BSI-related mortality, we initiated active screening from September 2017 in an attempt to identify CRE-colonized patients and to reduce the rate of CRE BSIs. This study aimed to evaluate the effect of CRE screening and intervention measures in the prevention and control of CRE BSI during the early stage of transplantation.

Patients and methods

Patients and study design

This was a retrospective observational study of 395 consecutive patients who underwent HSCT in our center from September 2017 to April 2019. From September 2017 to June 2018 (period 1), we implemented single CRE rectal screening within 1 week before transplantation. From July 2018 to April 2019 (period 2), to improve the positive detection rate, we implemented continuous weekly screening until hematopoietic reconstruction. CRE screening would be repeated in patients who had fever or underwent gut complications, such as abdominal pain, diarrhea and perianal inflammation. Data retrospectively collected from the two periods were compared. The CRE gut colonization rate, CRE BSI rate and attributed mortality at day 30 from the positivity of blood cultures were evaluated. Informed consent for HSCT, collection of stool swabs, data analysis, and publication was obtained from patients. The study protocol complied with the Declaration of Helsinki.

Surveillance

Stool was the surveillance material in our center. Specimens were collected in an aseptic manner and immediately transported to the microbiology laboratory. The technician inoculated the samples on Columbia blood agar for microbial identification, and antibiotic susceptibility testing was performed. CRE was defined as any isolated Enterobacteriaceae resistant to meropenem (disc diffusion diameter ≤ 19 mm), ertapenem (MIC ≥ 2 μg/ml) or imipenem (MIC≥4 μg/ml) [19]. Patients who had a positive stool swab for CRE during the screening period were defined as colonized, while patients who continuously tested negative for CRE during the whole screening period were defined as noncolonized [14].

Targeted managements of CRE colonization

For patients colonized with CRE, contact precautions were applied, including a single room, a hanging sign, hand hygiene performed before and after entering the room, use of disposable gloves and gowns and strengthened environmental cleaning and disinfection. Patients who were colonized with CRE but had no fever also received contact precaution but were not treated with prophylactic antibiotics.

A single oral temperature of ≥38.3 °C or a persistent oral temperature > 38.0 °C sustained over 1 h was defined as fever, and an absolute neutrophil count (ANC) below 0.5 × 10^9/L was defined as neutropenia in this study [20]. CRE BSI was diagnosed with the collection of blood cultures that yielded a CRE strain. When the colonized patient exhibited febrile episodes, treatment was conducted according to the patient’s condition, neutropenic severity, infection clinical symptoms and laboratory examination. At least two consecutive blood cultures were sent before starting antibiotics for patients with clinical symptoms. Preemptive CRE-targeted treatment with tigecycline was performed under all the following conditions: (i) CRE...
colonization identified at the onset of fever; (ii) neutropenic fever persistent over 12 h or fever with obvious symptoms of intestinal infection, such as abdominal pain, diarrhea, and perianal pain; and (iii) C-reactive protein (CRP) at 5 times higher than normal with or without a significant increase in procalcitonin (PCT). Polymyxin was added if there were signs of progression of sepsis or if there was a lack of response for tigecycline treatment within 48 h [18, 21].

**Statistical analysis**

Data analyses were performed with SPSS (version 20.0 SPSS Inc., IBM Co., Chicago, IL, USA). Continuous variables were evaluated using the Kruskal-Wallis test; categorical variables were evaluated with Fisher’s exact test or Pearson chi square test. All tests and P-values were two-sided, and a P-value < 0.05 was considered statistically significant.

**Results**

**Patient characteristics**

A total of 395 patients who underwent HSCT from September 2017 to April 2019 were evaluated. Two hundred and twenty-one (55.9%) were male, and 174 (44.1%) were female, with a median age of 36 years (range, 9–67). Table 1 shows the demographic and clinical characteristics of the patients. There was no significant difference between the two groups in age, sex, underlying disease or type of HSCT.

**CRE detection rate, BSI incidence and clinical outcomes**

During period 1, 3 patients (3/200, 1.5%) were identified as colonized with CRE in the gut; one died of septic shock, and the other two survived. Four patients who were screened negative for CRE colonization before HSCT later developed CRE BSIs (4/200, 2%) during the HSCT period. Two (50%) out of the 4 patients died, as one patient died of CRE-related septic shock and the other of CRE BSI-induced thrombotic microangiopathy. During period 2, 21 (10.8%) out of 195 patients were identified to be colonized with CRE, which was a significantly higher percentage than that identified by single screening (p < 0.001). Among these patients, the median number of screening times performed in patients was 6 (ranging from 4 to 15 times): only 4 (19.0%) patients were identified as positive for CRE at the first screening, 5 (23.8%) at the second screening, and the remaining 12 (57.1%) at the third or more screening. One of these colonized patients with neutropenia subsequently developed CRE BSI (1/21, 4.8%) but survived (Table 2).

**Targeted managements**

Twenty-four patients (3 detected during period 1 and 21 detected during period 2) were identified to be colonized with CRE in the gut, and the clinical manifestations are summarized in Table 3. Among the 3 patients who received a single screening, 2 patients were positive for CRE screening before transplantation and developed fever at day +7 and day +5 after screening. They

---

**Table 1** Baseline demographic and clinical characteristics of the study population

| Variable                  | Single screening group (N = 200) | Continuous screening group (N = 195) | P Value |
|---------------------------|----------------------------------|-------------------------------------|---------|
| Age, median (range)       | 35.7(9–64)                       | 37.2(12–67)                         | 0.319   |
| Sex, N (%)                |                                  |                                     |         |
| Male                      | 115(57.5)                        | 106(54.4)                           | 0.530   |
| Female                    | 85(42.5)                         | 89(45.6)                            |         |
| Underlying disease, N (%) |                                  |                                     |         |
| AML                       | 78(39.0)                         | 66(33.8)                            |         |
| ALL                       | 62(31.0)                         | 66(33.8)                            |         |
| MDS                       | 18(9.0)                          | 9(4.6)                              |         |
| NHL/HL                    | 21(10.5)                         | 20(10.3)                            |         |
| MM                        | 12(6.0)                          | 20(10.3)                            |         |
| others                    | 9(4.5)                           | 14(7.2)                             |         |
| Type of HSCT, N (%)       |                                  |                                     | 0.697   |
| Allogeneic                |                                  |                                     |         |
| MUD                       | 13(6.5)                          | 14(7.2)                             |         |
| Haplo                     | 127(63.5)                        | 117(60.0)                           |         |
| Sib                       | 37(18.5)                         | 34(17.4)                            |         |
| Autologous                | 23(11.5)                         | 30(15.4)                            |         |

Abbreviations: AML Acute myeloid leukemia, ALL Acute lymphatic leukemia, MDS Myelodysplastic syndrome, NHL Non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM Multiple myeloma, MUD Matched-unrelated donor allogeneic HSCT, Haplo HLA-Haploidentical allogeneic HSCT, Sib HLA-sibling allogeneic HSCT
resistance to antibiotics was exactly consistent between colonization subsequently developed a CRE BSI, and the 24) of CRE colonization. One patient with CRE colonization. Patients diagnosed as CRE colonization, N (%) 3(1.5%) 21(10.8%) Without screening (N = 311) Single screening (period 1, n = 200) Continuous screening (period2, n = 195) CRE BSIs, N (%) 6 (1.9%) 4(2.0%) 1(0.5%) patients with CRE colonization 0 4 0 patients without CRE colonization 6 0 1 Mortality in patients with CRE BSI, N (%) 4 (66.7%) 2(50.0%) 0

Microbiological data
CRE strains were isolated from 11 patients in blood cultures, including strains detected in the unscreened phase and 24 patients in stool swabs during the screening period (the first positive result was documented for samples from the same origin), revealing 22 K. pneumoniae and 13 E. coli. K. pneumoniae was predominant, accounting for 81.8% of CRE BSIs (9/11) and 54.2% (13/24) of CRE colonization. One patient with CRE colonization subsequently developed a CRE BSI, and the resistance to antibiotics was exactly consistent between blood culture and stool samples. The resistance rates to antibiotics of the 35 CRE isolates are shown in Table 4. Among the three carbapenems (meropenem, imipenem and ertapenem), there was a slight difference in the antibiotic resistance rate of the two strains, which cannot be ruled out for technical reasons. The resistance rates of tigecycline and amikacin were 0 and 28.6%, respectively.

Discussion
CRE BSIs have become a major challenge and are associated with high mortality. In China, the overall annual CRE incidence is approximately 4 per 10,000 discharges, with the highest rates in some regions (0.15%) where CRE is highly endemic and causes a severe disease burden [22]. Active surveillance for CRE colonization as part of a multifactorial intervention is an effective strategy to decrease nosocomial CRE infection rate and CRE-related mortality [20, 23, 24]. CRE screening with stool is considered an effective method for surveillance of CRE colonization.

Before the implementation of active screening, the incidence and attributable mortality of CRE BSI in our center were high (1.9 and 66.7%, respectively) and similar to those in previous studies. Thus, we initiated active surveillance in HSCT recipients. During period 1, only 1.5% of patients were identified as positive for CRE, and the 4 patients who developed CRE BSIs were negative at the single screening. The incidence and mortality of CRE BSIs were 2 and 50%, respectively. These results suggested that single screening could not effectively discriminate colonized patients. Considering the poor efficiency, we started continuous weekly screening during period 2, and a significant difference was observed with respect to the CRE detection rate (1.5% vs 10.8%, P < 0.001). Additionally, it is worth noting that of the patients who were positive in continuous screening, only 4 were positive at the first screening, and 80.9% (17 out of 21 colonized patients) turned positive results for CRE at the second or later screening, which again suggests the deficiencies of single screening. Moreover, due to the increased positive rate of continuous screening and the preemptive treatments used in these patients with infectious symptoms, the morbidity and mortality of CRE.

Table 2 Implementation rate and results of CRE screening

| Without screening (N = 311) | Single screening (period 1, n = 200) | Continuous screening (period2, n = 195) |
|---------------------------|------------------------------------|----------------------------------------|
| Patients diagnosed as CRE colonization, N (%) | 3(1.5%) | 21(10.8%) |
| CRE BSIs, N (%) | 6 (1.9%) | 4(2.0%) | 1(0.5%) |
| patients with CRE colonization | 0 | 4 | 0 |
| patients without CRE colonization | 6 | 0 | 1 |
| Mortality in patients with CRE BSI, N (%) | 4 (66.7%) | 2(50.0%) | 0 |
Table 3: Clinical manifestations of the 24 patients colonized with CRE

| Pt | Age /Sex | Disease/ HSCT | CRE Isolate | Which times screening turned positive | Febrile episodes in carriers | Time from colonization to fever (day) | Time from fever to the use of tigecycline (hour) | ANC at fever (x 10^9/L) | Symptoms at fever | CRP (mg/L) /PCT (µg/L) | 30 days status |
|----|----------|---------------|-------------|--------------------------------------|-----------------------------|--------------------------------------|---------------------------------------------|------------------------|----------------|-------------------|-----------------|
| 1ª | 36/F     | ALL/ Haplo    | E. coli     | Yes                                  | −3                          | > 72                                 | 0                                          | Abdominal pain, diarrhoea | 216.8/1.0     | Dead              |                  |
| 2  | 56/F     | MM/ Auto      | E. coli     | Yes                                  | 7                           | < 24                                 | 0                                          | Chills, tremble          | 95.1/4.1       | Alive             |                  |
| 3  | 32/m     | ALL/ MUD      | K.pneumoniae| Yes                                  | 5                           | < 24                                 | 0                                          | No                     | 48.9/normal     | Alive             |                  |
| 4  | 36/M     | AML/ Haplo    | K. pneumoniae| No                                   | /                           | /                                    | /                                          | /                      | /              | Alive             |                  |
| 5  | 15/M     | AML/ Haplo    | E. coli     | Yes                                  | 9                           | < 24                                 | 0                                          | Chills, tremble          | 73.0/normal     | Alive             |                  |
| 6  | 27/M     | ALL/ Haplo    | E. coli     | Yes                                  | 8                           | < 24                                 | 0                                          | No                     | 52.2/normal     | Alive             |                  |
| 7  | 48/M     | AML/ Haplo    | E. coli     | Yes                                  | 4                           | < 24                                 | 0                                          | Perianal inflammation    | 112.3/normal    | Alive             |                  |
| 8  | 45/M     | AML/ Haplo    | K. pneumoniae| No                                   | /                           | /                                    | /                                          | /                      | /              | Alive             |                  |
| 9  | 40/M     | AL/ Haplo     | K. pneumoniae| No                                   | /                           | /                                    | /                                          | /                      | /              | Alive             |                  |
| 10 | 38/M     | T-LBL/ Haplo  | E. coli     | Yes                                  | 11                          | < 24                                 | 0.5                                         | No                     | 43.2/normal     | Alive             |                  |
| 11 | 16/F     | ALL/ Haplo    | E. coli     | Yes                                  | 17                          | < 24                                 | 0                                          | No                     | 54.2/normal     | Alive             |                  |
| 12 | 18/M     | ALL/ MUD      | E. coli     | Yes                                  | 9                           | < 24                                 | 0                                          | Chills, tremble          | 64.5/normal     | Alive             |                  |
| 13 | 25/M     | ALL/ Haplo    | E. coli     | Yes                                  | 8                           | < 24                                 | 0                                          | No                     | 61.2/normal     | Alive             |                  |
| 14 | 34/F     | AML/ Haplo    | K. pneumoniae| No                                   | /                           | /                                    | /                                          | /                      | /              | Alive             |                  |
| 15 | 44/M     | MM/ Auto      | E. coli     | No                                   | /                           | /                                    | /                                          | /                      | /              | Alive             |                  |
| 16 | 50/M     | AML/ Sib      | K. pneumoniae| Yes                                  | 15                          | < 24                                 | 0                                          | sore throat             | 70.4/normal     | Alive             |                  |
| 17 | 18/M     | ALL/ Haplo    | K. pneumoniae| No                                   | /                           | /                                    | /                                          | /                      | /              | Alive             |                  |
| 18 | 51/M     | ALL/ Haplo    | E. coli     | No                                   | /                           | /                                    | /                                          | /                      | /              | Alive             |                  |
### Table 3  Clinical manifestations of the 24 patients colonized with CRE (Continued)

| Pt |Pt Age /Sex | Disease/ HSCT | CRE Isolate | Which times screening turned positive | Febrile episodes in carriers | Time from colonization to fever (day) | Time from fever to the use of tigecycline (hour) | ANC at fever (×10^9/L) | Symptoms at fever | CRP (mg/L) /PCT (μg/L) | 30 days status |
|----|-------------|---------------|-------------|--------------------------------------|-----------------------------|-------------------------------------|---------------------------------|----------------|----------------|----------------|---------------|----------------|
| 19 | 22/M        | ALL/ Haplo    | K. pneumoniae 4 | No                                | /                           | /                                 | /                                | /              | /              | /              | Alive         |
| 20 | 22/F        | AML/ Haplo    | K. pneumoniae 3 | Yes                               | 1                           | > 48                               | 0                                | Chills, tremble | 65.2/0.6       | Alive          |
| 21 | 26/M        | ALL/ MUD      | K. pneumoniae 1 | Yes                               | 13                          | < 24                               | 0                                | No             | 73.4/normal | Alive          |
| 22 | 27/M        | ALL/ Haplo    | K. pneumoniae 6 | No                                | /                           | /                                 | /                                | /              | /              | /              | Alive         |
| 23 | 21/M        | AML/ Haplo    | K. pneumoniae 2 | Yes                               | 12                          | < 24                               | 0                                | Perianal inflammation | 307/ normal | Alive          |
| 24 | 62/M        | AML/ Haplo    | K. pneumoniae 6 | Yes                               | 2                           | < 24                               | 0                                | 141.7/normal | Alive          |

**Abbreviations:** AML, Acute myeloid leukemia; ALL, Acute lymphatic leukemia; AL, Acute leukemia; Auto, Autologous HSCT; CRP C-reactive protein (normal value: 0-8 mg/L); E.coli, Escherichia coli; Haplo, HLA-Haploidentical allogeneic HSCT; K.pneumoniae, Klebsiella pneumoniae; MM, Multiple myeloma; MUD, Matched-unrelated donor allogeneic HSCT; PCT, Procalcitonin (normal value:< 0.5 μg/L); Sib, HLA-sibling allogeneic HSCT; T-LBL, T-lymphoblastic lymphoma.

*a*The patient 1: single screening was negative for the patient, but subsequent screening indicated positive 3 days after the onset of fever and the patient died of septic shock.

1. Four patients (2, 12, 20, 23) were combined with polymyxin because of persistent fever after 48 h of tigecycline treatment, one of them (patient 20) developed CRE BSIs later.
BSIs showed a trend of reduction (only 0.5 and 0%, respectively), for which the difference was not statistically significant, probably owing to the small sample size. Forcina et al. also demonstrated that after the introduction of regular surveillance, the cumulative incidence in CRE BSI and septic shock at 1 year after HSCT was significantly reduced [4]. The CRE infection mortality dropped from 62.5 to 16.6%. These results strongly support the key role of continuous screening in the prevention and control of CRE BSI.

Consistent with published data, the resistance rate to tigecycline in our study was low, at 0%, and tigecycline was also used as the first-line antibiotic for CRE infection in our study [2, 25, 26]. Clinical signs of infection are usually attenuated or absent in neutropenic patients, and fever is often the only symptom of a serious potential infection. In order to manage patients colonized with CRE, who are at high risk of developing BSIs, we conducted contact precaution and preemptive CRE targeted treatment. Early targeted antibiotic therapy is considered vital to cover possible infections in febrile neutropenic patients with CRE colonization even if blood cultures remain negative [20, 27–30]. In our study, we administered preemptive treatment with tigecycline in the initial 24 h following fever onset to patients with CRE colonization combined with neutropenic fever/clinical signs of infection/significant elevation of inflammatory markers, and controlled temperature rapidly. However, 2 patients with neutropenic fever received tigecycline later than 24 h after fever onset. One received tigecycline 72 h since the single screening was negative and ultimately died of septic shock. The other subsequently developed a CRE BSI but survived due to timely combination with polymyxin (changed later to ceftazidime-avibactam because of the nephrotoxicity). These results also highlight that for CRE colonized patients with febrile neutropenia and clinical signs of infection, prompt and active targeted CRE treatment contribute to improvement of prognosis [4, 31]. For patients colonized with CRE without fever, contact precaution is necessary, while the administration of antibiotics should be cautious and avoid abuse. In our study, patients colonized with CRE in the absence of febrile episodes were only isolated and observed, did not receive tigecycline treatment and got favorable prognosis. These results also suggest that gut CRE colonization alone is not an indication for further antibiotic treatment.

There are several limitations of this study. First, this was a single-center, retrospective observational study in a particular geographical area. Second, the resistance mechanism has not been well investigated. Finally, the cohort of patients with CRE colonization or CRE BSIs was small. A multicenter, prospective study is being carried out in our center to further demonstrate the optimal surveillance methods for CRE colonization in HSCT patients.

**Conclusion**

In summary, for patients who undergo HSCT, regular continuous screening for CRE colonization is necessary to assist in the early detection and management of CRE colonizers, including contact precaution and prompt implementation of CRE-targeted preemptive treatment to

| Antibiotics            | CRE resistance rate in stool samples | CRE resistance rate in blood cultures |
|------------------------|--------------------------------------|---------------------------------------|
|                        | Total (24)                           | E.coli (11, 45.8%)                    | Total (11)                           | k.pneumoniae (9, 81.8%) | E.coli (2, 18.2%) |
| Ceftazidime            | 100%                                 | 100%                                  | 100%                                 | 100%                     | 100%                      |
| Ceftriaxone            | 100%                                 | 100%                                  | 100%                                 | 100%                     | 100%                      |
| Cefepime               | 100%                                 | 100%                                  | 100%                                 | 100%                     | 100%                      |
| Piperacillin/tazobactam| 100%                                 | 100%                                  | 100%                                 | 100%                     | 100%                      |
| Fluoroquinolones       | 95.8%                                | 90.9%                                 | 100%                                 | 100%                     | 100%                      |
| Gentamicin             | 82.6%                                | 84.6%                                 | 80.0%                                | 63.6%                    | 66.7%                     |
| Amikacin               | 16.7%                                | 23.1%                                 | 9.1%                                 | 54.5%                    | 66.7%                     |
| Aztreonam              | 79.2%                                | 92.3%                                 | 63.6%                                | 100%                     | 100%                      |
| Meropenem              | 100%                                 | 100%                                  | 100%                                 | 83.3%                    | 100%                      |
| Imipenem               | 91.6%                                | 92.3%                                 | 90.9%                                | 100%                     | 100%                      |
| Ertapenem              | 100%                                 | 100%                                  | 100%                                 | 100%                     | 100%                      |
| Tigecycline            | 0                                    | 0                                     | 0                                    | 0                        | 0                         |
| SMZ co                 | 91.7%                                | 84.6%                                 | 100%                                 | 81.8%                    | 77.8%                     |
| Nitrofurantin          | /                                    | /                                     | NR                                   | 77.8%                    | 100%                      |
| Tobramycin             | /                                    | /                                     | NR                                   | 77.8%                    | 85.7%                     |

**Abbreviations:** E.coli *Escherichia coli*, K.pneumoniae *Klebsiella pneumoniae*, SMZ co *Compound Sulfamethoxazole*
improve outcomes in patients after HSCT with CRE BSIs. Regular continuous gut screening is recommended as a feasible and reliable measure for HSCT patients at high risk of infection.

**Abbreviations**
BSI: Bloodstream infection; CRE: Carbapenem-resistant Enterobacteriaceae; CRP: C-reactive protein; E. coli: Escherichia coli; HSCT: Hematopoietic stem cell transplantation; K. pneumoniae: Klebsiella pneumoniae; PCT: Procalcitonin

**Acknowledgments**
Not applicable.

**Authors’ contributions**
JMS and HH designed the study. QY and HCC collected the data. YL, YMZ, and XPL analyzed the data and wrote the first draft of the manuscript, which was significantly edited by JMS. All authors read and approved the final manuscript.

**Funding**
This work was funded by the National Natural Science Foundation of China (grant nos.81730008 and 81870153) and Science and Technology Department of Zhejiang Province (grant no. 2015C03038).

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**
Neither medical nor ethical approval was required to conduct the surveillance since it was part of the local hospital policy, patients provided oral informed consent and all data were processed anonymously. The, non-invasive, rectal swabs were collected as part of the local hospital policy which is considered routine care. The weekly performed surveys for the presence of Carbapenem-resistant Enterobacteriaceae are part of the infection control policy in our hospital. This includes contact tracing, active search in patients with risk factors and routinely check-ups like the yearly prevalence survey. Swabs were not specifically collected for the purposes of this publication.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China.
2Institute of Hematology, Zhejiang University, Hangzhou, China.
3Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China.
4Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
5Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, 79 Qingchun Road, Hangzhou, China.

**Received:** 9 January 2020  **Accepted:** 2 March 2020

**Published online:** 17 March 2020

**References**
1. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S528–36.
2. Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, Li Y, Liao K, Chen S. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine. 2017;19:98–106.
3. Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017;8(4):391–402.
4. Forcina A, Baldan R, Marasco V, Cicherò P, Bondanza A, Novello M, Piemontese S, Soliman C, Greco R, Lorentino F, et al. Control of Infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(1):114–9.
5. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58(9):1274–83.
6. Girmenia C, Rossolini GM, Picotti G, Bertaina A, Priapà G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50(2):282–8.
7. Tischendorf J, de Avila RA, Saffar N. Risk of infection following colonization with carbapenem-resistant Enterobacteriaceae: a systematic review. Am J Infect Control. 2016;44(5):539–43.
8. Scheich S, Lindner S, Koenig R, Reinheimer C, Wielchuska TA, Hogardt M, Besier S, Kempf VAI, Kessel J, Martin H, et al. Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Cancer. 2018;124(2):86–96.
9. Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, Feldman EJ, Roboz JG, Shore TB, Hellgott DC, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma. 2013;54(4):799–806.
10. Satlin MJ, Cohen N, Ma KC, Gerdelmitz E, Soave R, Askim G, Chen L, Keiwirth BN, Walsh TJ, Seo SK. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Inf Secur. 2016;73(4):336–45.
11. McConville TH, Sullivan SB, Gomez-Simmonds A, Whitteir S, Uhlemann AC. Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients: an observational study. PLoS One. 2017;12(10):e0186195.
12. Dickstein Y, Edelman R, Dior T, Hussen K, Bar-Lavie Y, Paul M. Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers. J Hosp Infect. 2016;94(1):54–9.
13. Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2014;58(5):697–703.
14. World Health Organization. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. Geneva: World Health Organization; 2017.
15. Girmenia C, Viscoli C, Picotti G, Cudillo L, Batti S, Enrico A, Sarmati L, Ciceri F, Locatelli F, Giannella M, et al. Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica. 2015;100(9):E373–6.
16. Richter SS, Marchain D. Screening for carbapenem-resistant Enterobacteriaceae: who, when, and how? Virulence. 2017;8(4):417–26.
17. Magiorakos AP, Bums K, Rodriguez Bano J, Berg M, Dainos G, Dumps U, Lucet JC, Moro ML, Taconelli E, Simonsen GS, et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control. 2017;6:113.
18. Centers for Disease Control. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). Atlanta: Department of Health & Human Services; 2015. Update CRE Toolkit.
19. The Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: CLSI supplement M100. 28th ed. Wayne: Clinical and Laboratory Standards Institute; 2018.
20. Freifeld AG, Bow EJ, Sepkowitz KA, Bodeck MJ, Ro JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93.
21. Jaishwal SR, Gupta S, Kumar RS, Sherawat A, Rajoreya A, Dash SK, Bhagwati G, Chakraborti S. Gut colonization with carbapenem-resistant Enterobacteriaceae adversely impacts the outcome in patients with...
hematological malignancies: results of a prospective surveillance study. Mediterr J Hematol Infect Dis. 2018;10(1):e2018025.

22. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, Xie L, Yang C, Ma X, Li H, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network. Antimicrob Agents Chemother. 2018;62(2):e01882–17.

23. Ben-David D, Maor Y, Regev-Yochay G, Tal I, Shachar D, Zlotkin A, Smolian G, Rahav G. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Cont Hosp Ep. 2010;31(6):e20–6.

24. Kidde A, Assawatheptawee K, Na-udorn A, Treebupatchakul P, Wangteeraprasert A, Walsh TR, Niimup PR. Risk factors for Gastrointestinal Colonization and acquisition of carbapenem-resistant Gram-Negative bacteria among patients in intensive Care Units in Thailand. Antimicrob Agents Ch. 2018;62(8):e00341–18.

25. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gysens IC, Kema WV, Kasaoka G, Marchetti O, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98(12):1826–35.

26. Sheu CC, Chang YT, Lin SY, Chen YH, Hseuh PR. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80.

27. Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, Fianchi L, Delia M, Sica S, Periello V, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–81.

28. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Cinocchio F, Cristini F, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–50.

29. Pagano L, Caira M, Trecarichi EM, Spanu T, Di Blasi R, Sica S, Sanguinetti M, Tumbarello M. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis. 2014;20(7):1235–6.

30. Tofas P, Skida A, Angelopoulou M, Sipsas N, Pavlopoulou I, Taoussi S, Pagoni M, Kotsopoulou M, Periorenzou S, Antoniadrou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47(4):335–9.

31. Miccozi A, Gentile G, Minotti C, Cartoni C, Capria S, Gallaro D, Santilli S, Parreri I, Grammatico S, Bucanee G, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17(1):203.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.